NEW YORK (GenomeWeb News) – Interleukin Genetics has filed a shelf registration with the US Securities and Exchange Commission seeking to sell up to $75 million worth of stock or debt instruments.
The firm said in its SEC registration that it may offer shares of common stock and preferred stock, debt securities, warrants, or rights or contracts for any of those securities, either individually or in units.
The Waltham, Mass.-based genetic testing company is developing gene-based prediction tests for tooth loss, osteoporosis, heart health, bone health, and risk tests for other conditions.
As of Sep. 30, Interleukin held $1.4 million in cash and cash equivalents.
Interleukin Genetics' stock closed down 5 percent at $.77 per share in Wednesday trade on the American Stock Exchange.